Basisstatistiken
| LEI | 529900C85NBMQFSETD92 |
| CIK | 1228627 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Opus Genetics, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 14, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Opus Genetics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value Other 950,000 $ 5.11 $ 4,854,500.00 0.0001381 $ 670.41 Total Offering Amounts: $ |
|
| May 14, 2026 |
FIFTH AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN Exhibit 4.10 FIFTH AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN WHEREAS, Opus Genetics, Inc. (the “Company”) has heretofore adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan, as amended (the “Plan”); and WHEREAS, the Company wishes to amend the Plan to increase the number of shares of common stock of the Company, par value $0.0001 per share, available for issuance under the Plan; N |
|
| May 14, 2026 |
As filed with the Securities and Exchange Commission on May 14, 2026 As filed with the Securities and Exchange Commission on May 14, 2026 Registration No. |
|
| May 12, 2026 |
Exhibit 10.5 Executed Version WAIVER AND OMNIBUS AMENDMENT OF NOTE PURCHASE AGREEMENT AND STOCK PURCHASE AND CONVERSION AGREEMENT April 13, 2026 This Waiver and Omnibus Amendment (this “Amendment”), dated as of the date first set forth above, is entered into by and among Opus Genetics, Inc., a Delaware corporation (the “Company”), OpusTX, LLC, a Delaware limited liability company (the “Guarantor” |
|
| May 12, 2026 |
Exhibit 99.1 Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA's Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial RDH12 |
|
| May 12, 2026 |
AMENDMENT NO. 2 TO CONSULTING AGREEMENT Exhibit 10.6 AMENDMENT NO. 2 TO CONSULTING AGREEMENT This AMENDMENT NO.2 (“Amendment No. 2”) to the CONSULTING AGREEMENT dated April 11, 2024 and amended November 21, 2024 (the “Agreement”) between OPUS GENETICS INC., a Delaware corporation having its principal place of business at 8 Davis Drive, Durham, NC, 27713 (the “Company”), and JAY S. PEPOSE MD, whose address is 1125 Templeton Place, Cheste |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Opus Genetics, Inc. |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 12, 2026 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF OPUS GENETICS, INC. (Pursuant to Sections 141 and 242 of the General Corporation Law of the State of Delaware) Opus Genetics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Delaware General Corporati |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| April 21, 2026 |
As filed with the Securities and Exchange Commission on April 20, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 20, 2026 Registration No. |
|
| April 21, 2026 |
April 21, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jessica Dickerson Re: Opus Genetics, Inc. Registration Statement on Form S-3 File No. 333-294295 Acceleration Request Requested Date: April 22, 2026 Requested Time: 4:00 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Sec |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| April 7, 2026 |
Exhibit 99.1 April 6, 2026 Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment - - Strategic financing to accelerate development of earlier-stage gene ther |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| April 7, 2026 |
Form of Opus Genetics Inc. Change in Control Bonus Payment Agreement EXHIBIT 10.1 Form of Opus Genetics Inc. Change in Control Bonus Payment Agreement Whereas, Opus Genetics Inc. (the “Company”) wishes to ensure that its executives, including [name and title of executive] (the “Executive”) avoid certain distractions related to parachute payment excise taxes in connection with any change in control of the Company. Therefore, the Company and the Executive, as of the |
|
| April 7, 2026 |
Exhibit 10.1 Execution Version NOTE PURCHASE AGREEMENT dated as of April 2, 2026 among OPUS GENETICS, INC. as Issuer, THE OTHER OBLIGORS PARTY HERETO, THE PURCHASERS PARTY HERETO, and OPCM SA LLC as Purchaser Agent TABLE OF CONTENTS Page ARTICLE I ACCOUNTING AND OTHER TERMS 1 ARTICLE II NOTES; TERMS OF PAYMENT; REVENUE PARTICIPATION 2 Section 2.1 Purchase and Sale of Notes 2 Section 2.2 Payments o |
|
| April 7, 2026 |
STOCK PURCHASE AND CONVERSION AGREEMENT Execution Version Exhibit 10.2 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE STOCK PURCHASE AND CONVERSION AGREEMENT This STOC |
|
| March 23, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Prelimin |
|
| March 23, 2026 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K ☒ AnnualreportpursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934. FortheFiscalYearEndedDecember31,2025 or □ TransitionreportpursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934. Forthetransitionperiodfrom to CommissionFileNo.001-34079 OpusGenetics,Inc. (Exactnameofregistrantasspecifiedinitscharter) Delaware 11 |
|
| March 17, 2026 |
March 17, 2026 George Magrath Chief Executive Officer Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, NC 27713 Re: Opus Genetics, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294295 Dear George Magrath: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelerat |
|
| March 13, 2026 |
As filed with the Securities and Exchange Commission on March 13, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 13, 2026 Registration No. |
|
| March 13, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Opus Genetics, Inc. |
|
| March 12, 2026 |
Exhibit 4.13 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of securities of Opus Genetics, Inc. (the “Company,” “we,” “our,” or “us”) provides a summary of the rights of our capital stock as well as certain provisions of our Restated Certificate of Incorporation, as amended (our “Certificate of Incorpor |
|
| March 12, 2026 |
PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED MARCH 12, 2026 TABLE OF CONTENTS PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED MARCH 12, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-34079 Opus Genetics, Inc. (Exact |
|
| March 12, 2026 |
AMENDMENT NO. 1 TO CONSULTING AGREEMENT Exhibit 10.16.1 AMENDMENT NO. 1 TO CONSULTING AGREEMENT This AMENDMENT NO.1 (the “Amendment”) to the CONSULTING AGREEMENT (the “Agreement”) dated April 11, 2024 by and between OCUPHIRE PHARMA, INC., a Delaware corporation having its principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335 (the “Company”), and JAY S. PEPOSE M.D., having an address at 1125 Templ |
|
| March 12, 2026 |
LIST OF SUBSIDIARIES Subsidiaries of Opus Genetics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of Opus Genetics, Inc. Subsidiaries Jurisdiction of Incorporation OPUSTX, LLC Delaware |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| March 10, 2026 |
Exhibit 99.1 Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ de |
|
| February 19, 2026 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 18, 2026, by and among Opus Genetics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (each, an “Investor” and collectively, together with their respective permitted assigns, the “Investors”). Capitalized terms used herein |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission F |
|
| February 19, 2026 |
Exhibit 3.1 Execution Version OPUS GENETICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Opus Genetics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly |
|
| February 19, 2026 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT BY AND AMONG OPUS GENETICS, INC. AND THE PURCHASERS AS SET FORTH HEREIN FEBRUARY 13, 2026 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 4 2.1 Purchase and Sale 4 2.2 Closing 4 3. Representations and Warranties of the Company 5 3.1 Subsidiaries; Organization and Power 5 3.2 Capitalization 5 3.3 Registration Rights |
|
| January 22, 2026 |
As filed with the Securities and Exchange Commission on January 22, 2026 As filed with the Securities and Exchange Commission on January 22, 2026 Registration No. |
|
| January 22, 2026 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) OPUS GENETICS, INC. |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 12, 2026 |
Exhibit 99.1 Delivering on the Promise ofGene Therapy for Rare Inherited Retinal Diseases January 2026 Nargiza,BEST1 patient This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from and future enrollment for our clinical trials and our pipeline o |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 8, 2026 |
Exhibit 99.1 Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - Multi-asset pipeline with significant targeted data readouts and milestones - - Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 - - Supplemental New Drug Application (sNDA) submitted for partnered presbyopia treatment - - Corporate presentation at J.P. Morgan Healthcare |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission F |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Opus Genetics, Inc. |
|
| November 12, 2025 |
Side Letter to the License and Collaboration Agreement Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. Side Letter to the License and Collaboration Agreement FamyGen Life Sciences, Inc. (“FamyGen”) and Opus Genetics, Inc. f/k/a Ocuphire Pharma Inc., (“Opus”) (e |
|
| November 12, 2025 |
Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update - Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision - - Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 - - OPGx-BEST1 gene the |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission F |
|
| November 6, 2025 |
Exhibit 99.1 FINAL FOR GLOBENEWSWIRE Opus Genetics Announces $23 Million Registered Direct Offering - Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C. – November 6, 2025 - Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”) a clinical-stage |
|
| November 6, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276462 Prospectus Supplement (To Prospectus dated January 23, 2024) 3,827,751 Shares of Common Stock Pre-Funded Warrants to Purchase 7,177,033 Shares of Common Stock 7,177,033 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrants We are offering 3,827,751 shares of common stock, par value $0.0001 (the “com |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 6, 2025 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated November 5, 2025 Relating to Prospectus Supplement dated November 5, 2025 Registration Statement No. |
|
| November 6, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT OPUS GENETICS, INC Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT OPUS GENETICS, INC Warrant Shares: Initial Exercise Date: November 7, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the dat |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 6, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 5, 2025, between Opus Genetics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| November 6, 2025 |
Exhibit 99.2 FINAL FOR GLOBENEWSWIRE Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease • Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 • First participant enrolled in run-in period for planned adapt |
|
| September 30, 2025 |
OPGx-LCA5 Phase 1/2 Trial Results September 30, 2025 Alan,LCA5 patient Exhibit 99. |
|
| September 30, 2025 |
Exhibit 99.1 Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities - Lasting, durable responses observed out to 18 months in adult participants - Expected FDA Me |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission |
|
| September 26, 2025 |
As filed with the Securities and Exchange Commission on September 26, 2025 As filed with the Securities and Exchange Commission on September 26, 2025 Registration No. |
|
| September 26, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) OPUS GENETICS, INC. |
|
| September 10, 2025 |
FOURTH AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN Exhibit 4.8 FOURTH AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN WHEREAS, Opus Genetics, Inc. (the “Company”) has heretofore adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan, as amended (the “Plan”); and WHEREAS, the Company wishes to amend the Plan to increase the number of shares of common stock of the Company, par value $0.0001 per share, available for issuance under the Plan; N |
|
| September 10, 2025 |
THIRD AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN Exhibit 4.7 THIRD AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN WHEREAS, Opus Genetics, Inc. (the “Company”) has heretofore adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan, as amended (the “Plan”); and WHEREAS, the Company wishes to amend the Plan to increase the number of shares of common stock of the Company, par value $0.0001 per share, available for issuance under the Plan; NO |
|
| September 10, 2025 |
As filed with the Securities and Exchange Commission on September 10, 2025 As filed with the Securities and Exchange Commission on September 10, 2025 Registration No. |
|
| September 10, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) OPUS GENETICS, INC. |
|
| September 2, 2025 |
Exhibit 10.1 Employment Agreement THIS EMPLOYMENT AGREEMENT (this “Agreement”) by and between Opus genetics inc., a Delaware corporation (the “Company”) and Robert Gagnon (the “Employee”) is executed as of August 29, 2025 (the “Execution Date”). Recitals Whereas, the Company and the Employee desire to enter into this Agreement to embody the terms of the Employee’s relationship as the Company’s Chi |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 2, 2025 |
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer Exhibit 99.1 Opus Genetics Appoints Rob Gagnon as Chief Financial Officer RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 - Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Opus Genetics, Inc. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2025 |
Exhibit 99.1 Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update - Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from |
|
| August 13, 2025 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. Execution Version FUNDING AND LICENSE AGREEMENT by and among Opus Genetics, Inc., OpusTX, LLC, Eyes On The Future, and The RDH12 Fund for Sight Dated July 22, |
|
| August 13, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. CONFIDENTIAL June 13, 2025 (“Effective Date”) George Magrath, M.D. Chief Executive Officer Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, NC 27709 Maxim |
|
| July 23, 2025 |
Exhibit 99.1 Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness - Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 (GLOBE NEWSWIRE) - Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical c |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 26, 2025 |
Up to $17,356,082 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276462 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated January 13, 2025 and Prospectus dated January 23, 2024) Up to $17,356,082 of Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated January 13, 2025, filed with the Securities and Exchange Commission as part of our registrati |
|
| June 26, 2025 |
Exhibit 99.1 Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia • Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity • Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the |
|
| June 26, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2025 |
Exhibit 99.1 Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program RESEARCH TRIANGLE PARK, N.C., June 23, 2025 - Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic diso |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Opus Genetics, Inc. |
|
| May 15, 2025 |
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update Exhibit 99.1 Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on track for IND filing and initiation of |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No.) 1. Name of the Registrant: Opus Genetics, Inc. 2. Name of Person Relying on Exemption: Mina Sooch 3. Address of Person Relying on Exemption: 6894 Lakemont Circle West Bloomfield, Michigan 48323 4. Written Materials. The following written material |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 9, 2025 |
Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, North Carolina Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, North Carolina April 9, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Attn: Joshua Gorsky; Joe McCann Re: Opus Genetics, Inc. Registration Statement on Form S-3 File No. 333-285038 Dear Messrs. Gorsky and McCann, Reference is made to the le |
|
| April 8, 2025 |
SIDLEY AUSTIN LLP ONE SOUTH DEARBORN STREET CHICAGO, IL 60603 +1 312 853 7000 +1 312 853 7036 FAX AMERICA • ASIA PACIFIC • EUROPE +1 312 853 7881 ANDREA. |
|
| April 8, 2025 |
As filed with the Securities and Exchange Commission on April 7, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 7, 2025 Registration No. |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 7, 2025 |
SIDLEY AUSTIN LLP ONE SOUTH DEARBORN STREET CHICAGO, IL 60603 +1 312 853 7000 +1 312 853 7036 FAX +1 312 853 7881 AMERICA • ASIA PACIFIC • EUROPE ANDREA. |
|
| April 4, 2025 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| April 4, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-276462 PROSPECTUS SUPPLEMENT (To prospectus dated January 23, 2024) Shares of Common Stock This prospectus supplement amends, supplements, and supersedes our prospectus dated January 23, 2024, relating to a purchase agreement, dated August 10, 2023 (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC, or Lincoln Park. The Purchase Agr |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION (Amendment No. ) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⊠ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 31, 2025 |
Exhibit 10.33 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] NON-EXCLUSIVE LICENSE AGREEMENT DATED AS OF MARCH 2, 2023 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND OPUS GENETICS, INC. TABLE OF CONTE |
|
| March 31, 2025 |
Exhibit 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of securities of Opus Genetics, Inc. (the “Company,” “we,” “our,” or “us”) provides a summary of the rights of our capital stock as well as certain provisions of our Restated Certificate of Incorporation, as amended (our “Certificate of Incorpor |
|
| March 31, 2025 |
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Exhibit 10.30.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW This Amendment No. 1 to Exclusive License Agreement with Know-How (“Amendment”) is made effecti |
|
| March 31, 2025 |
Exhibit 10.32 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] EXECUTION VERSION CONFIDENTIAL ASSET PURCHASE AGREEMENT by and between IVERIC BIO GENE THERAPY LLC and OPUS GENETICS INC. TABLE OF CONTENTS Article I DEFINITI |
|
| March 31, 2025 |
Exhibit 10.30.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] EXECUTION VERSION CONFIDENTIAL ASSIGNMENT CONSENT AGREEMENT AND THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Signature Page LICENSE CONT |
|
| March 31, 2025 |
Opus Genetics Announces Financial Results for Full Year 2024 Exhibit 99.1 Opus Genetics Announces Financial Results for Full Year 2024 Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance New capital supports delivery on key milestones for two lead gene therapy candidates OPGx- |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-34079 Opus Genetics, Inc. (Exact |
|
| March 31, 2025 |
OCUPHIRE PHARMA, INC. INSIDER TRADING COMPLIANCE POLICY Effective June 11, 2024 Exhibit 19 OCUPHIRE PHARMA, INC. INSIDER TRADING COMPLIANCE POLICY Effective June 11, 2024 This Insider Trading Compliance Policy (this “Policy”) consists of four sections: Section I provides an overview; Section II sets forth the policies of Ocuphire Pharma, Inc., a Delaware corporation (the “Company”) prohibiting insider trading; Section III explains insider trading; and Section IV consists of v |
|
| March 31, 2025 |
PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED MARCH 31, 2025 PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED MARCH 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2025 |
Exhibit 10.31 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] Final Execution Copy AMENDED AND RESTATED LICENSE AGREEMENT DATED AS OF JUNE 15, 2022 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND OPUS G |
|
| March 31, 2025 |
AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Exhibit 10.30.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW This Amendment No. 4 to Exclusive License Agreement with Know-How (“Amendment”) is made effecti |
|
| March 31, 2025 |
Exhibit 10.30 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] Execution Version EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Agreement No: L2011 By and among The Trustees of the University of Pennsylvania And The University |
|
| March 31, 2025 |
LIST OF SUBSIDIARIES Subsidiaries of Opus Genetics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of Opus Genetics, Inc. Subsidiaries Jurisdiction of Incorporation Orange Merger Sub II, LLC Delaware |
|
| March 31, 2025 |
AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Exhibit 10.30.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW This Amendment No. 2 to Exclusive License Agreement with Know-How (“Amendment”) is made effecti |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 28, 2025 |
March 28, 2025 Mina Sooch Nominating Shareholder Opus Genetics, Inc. 6894 Lakemont Circle West Bloomfield, MI 48323 Re: Opus Genetics, Inc. PREC14A Filed March 21, 2025 Filed by Mina Sooch et al. File No. 001-34079 Dear Mina Sooch: We have reviewed your filing and have the following comments. Please respond to these comments by providing the requested information or advise us as soon as possible w |
|
| March 24, 2025 |
COMMON STOCK PURCHASE WARRANT OPUS GENETICS, INC Exhibit 4.1 COMMON STOCK PURCHASE WARRANT OPUS GENETICS, INC CUSIP: 68406B Warrant Shares: Initial Exercise Date: March 24, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof ( |
|
| March 24, 2025 |
Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| March 24, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT OPUS GENETICS, INC Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT OPUS GENETICS, INC Warrant Shares: Initial Exercise Date: March 24, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| March 24, 2025 |
Exhibit 1.1 12,219,736 SHARES OF COMMON STOCK, 8,832,895 PRE-FUNDED WARRANTS AND 21,052,631 WARRANTS OF OPUS GENETICS, INC. UNDERWRITING AGREEMENT March 21, 2025 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, MN 55402 Ladies and Gentlemen: The unde |
|
| March 24, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276462 PROSPECTUS SUPPLEMENT (to Prospectus dated January 23, 2024) 12,219,736 Shares of Common Stock Warrants to Purchase up to 21,052,631 Shares of Common Stock Pre-Funded Warrants to Purchase 8,832,895 Shares of Common Stock Up to 29,885,526 Shares of Common Stock underlying the Warrants and Pre-Funded Warrants We are off |
|
| March 21, 2025 |
PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED MARCH 21, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 21, 2025 |
PREC14A 1 prec14a1439000203202025.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 21, 2025 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated March 21, 2025 Relating to Preliminary Prospectus Supplement dated March 21, 2025 Registration Statement No. |
|
| March 20, 2025 |
Amended and Restated Bylaws of Opus Genetics, Inc., effective as of March 19, 2025 OPUS GENETICS, INC. 8-K Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF OPUS GENETICS, INC. (A DELAWARE CORPORATION) March 19, 2025 ARTICLE I. OFFICES Section 1. Registered Office. The registered office of OPUS GENETICS, INC., a Delaware corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Office. The Corporation shall also |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 20, 2025 |
PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED MARCH 20, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 20, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| March 20, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276462 The information contained in this preliminary prospectus supplement is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer t |
|
| March 20, 2025 |
Issuer Free Writing Prospectus dated March 20, 2025 Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated March 20, 2025 Registration No. |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| February 26, 2025 |
February 26, 2025 George Magrath Chief Executive Officer Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, NC 27709 Re: Opus Genetics, Inc. Registration Statement on Form S-3 Filed February 18, 2025 File No. 333-285038 Dear George Magrath: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending your registratio |
|
| February 18, 2025 |
As filed with the Securities and Exchange Commission on February 18, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 18, 2025 Registration No. |
|
| February 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Opus Genetics, Inc. |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| January 24, 2025 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) between Opus Genetics, Inc., a Delaware corporation (the “Company”), and Nirav Jhaveri (the “Executive”) is entered into and made effective as of January 17, 2025 (the “Amendment Date”). WITNESSETH WHEREAS, the Company and Executive entered into that certain Employment Agreement, |
|
| January 24, 2025 |
Amended and Restated Employment Agreement Exhibit 10.1 Amended and Restated Employment Agreement THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) by and between Opus Genetics, Inc., a Delaware corporation (the “Company”), and George Magrath (the “Executive”) is entered into by the Company and the Executive and made effective as of January 17, 2025 (the “Effective Date”). Recitals Whereas, the Company and the Executive are |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 14, 2025 |
OPUS GENETICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT Exhibit 1.1 OPUS GENETICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT January 13, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Opus Genetics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance and Sal |
|
| January 13, 2025 |
Up to $40,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276462 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 23, 2024) Up to $40,000,000 Common Stock We have entered into a sales agreement (the “sales agreement”) with Leerink Partners LLC (“Leerink Partners”) relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement. In accor |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission |
|
| January 7, 2025 |
Condensed Financial Statements For the Nine Months Ended September 30, 2024 Exhibit 99.2 Opus Genetics Inc. Condensed Financial Statements For the Nine Months Ended September 30, 2024 1 Opus Genetics Inc. INDEX TO CONDENSED FINANCIAL STATEMENTS Condensed Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 3 Condensed Statement of Operations and Comprehensive Loss (unaudited) 4 Condensed Statement of Changes in Convertible Preferred Stock and Stockhol |
|
| January 7, 2025 |
Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA As of September 30, 2024 For the nine months ended September 30, 2024 and the year ended December 31, 2023 (Unaudited) Table of Contents Introduction 1 Unaudited Pro Forma Condensed Combined Balance Sheet 3 As of September 30, 2024 3 Unaudited Pro Forma Condensed Combined Income Statement 4 For the Nine Months Ended September 30, 2 |
|
| January 7, 2025 |
Exhibit 99.1 Opus Genetics Inc. Financial Statements Year Ended December 31, 2023 With Report of Independent Auditors 1 Opus Genetics Inc. INDEX TO FINANCIAL STATEMENTS Report of Independent Auditors 3 Balance Sheet 5 Statement of Operations and Comprehensive Loss 6 Statement of Changes in Convertible Preferred Stock and Stockholders’ Deficit 7 Statement of Cash Flows 8 Notes to Financial Statemen |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Opus Genetics, Inc. |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Opus Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission F |
|
| November 12, 2024 |
SECOND AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN Exhibit 10.3 SECOND AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN WHEREAS, Ocuphire Pharma, Inc. (the “Company”) has heretofore adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan, as amended (the “Plan”); and WHEREAS, the Company wishes to amend the Plan to increase the number of shares of common stock of the Company, par value $0.0001 per share, available for issuance under the Plan |
|
| November 12, 2024 |
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal diseases (IRDs) The pro forma cash balance of the combined company was approximately $37 million as of September 30, |
|
| November 12, 2024 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made as of October 22, 2024 (the “Effective Date”), between Ocuphire Pharma, Inc., a Delaware corporation, having a principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, Michigan 48335 (the “Company”), and Jean Bennett, M.D., Ph.D., having an address at 182 Fishers Road, Bryn Mawr, PA |
|
| November 12, 2024 |
Exhibit 10.1 Employment Agreement THIS EMPLOYMENT AGREEMENT (this “Agreement”) by and between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and Benjamin R. Yerxa, Ph.D. (the “Executive”) is signed by the Company and the Executive on October 22, 2024 (the “Effective Date”). Recitals Whereas, the Executive and Opus Genetics Inc. (“Opus”) are parties to that certain Employment Agreem |
|
| November 4, 2024 |
As filed with the Securities and Exchange Commission on November 4, 2024 As filed with the Securities and Exchange Commission on November 4, 2024 Registration No. |
|
| November 4, 2024 |
SECOND AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN Exhibit 4.6 SECOND AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN WHEREAS, Ocuphire Pharma, Inc. (the “Company”) has heretofore adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan, as amended (the “Plan”); and WHEREAS, the Company wishes to amend the Plan to increase the number of shares of common stock of the Company, par value $0.0001 per share, available for issuance under the Plan; |
|
| November 4, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) OPUS GENETICS, INC. |
|
| October 29, 2024 |
SC 13D 1 d856407dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Opus Genetics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 67577R102 (CUSIP Number) Russell Kelley, Managing Director Foundation Fighting Blindness Retinal Degeneration F |
|
| October 22, 2024 |
Exhibit 99.2 Delivering on the Promise of Ophthalmic Gene Therapy for Rare Inherited Retinal Diseases October 2024 Braydon, RDH12 patient This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning expectations regarding our cash runway, data from and future |
|
| October 22, 2024 |
CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OCUPHIRE PHARMA, INC. Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF OCUPHIRE PHARMA, INC. Ocuphire Pharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: ONE: The name of the corporation is Ocuphire Pharma, Inc. (the “Company”). TWO: The Company’s original Certificate of |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2024 OCUPHIRE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission |
|
| October 22, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: OCUPHIRE PHARMA, INC. a Delaware corporation; ORANGE MERGER SUB I, INC., a Delaware corporation; ORANGE MERGER SUB II, LLC, a Delaware limited liability company; and OPUS GENETICS INC. a Delaware corporation Dated as of October 22, 2024 THIS MERGER AGREEMENT IS SUBJECT TO REVISION BY THE PARTIES AT ANY TIME AND MUST BE KEPT CONFIDENTIAL IN ACCORDANCE |
|
| October 22, 2024 |
Exhibit 3.1 OCUPHIRE PHARMA, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ocuphire Pharma, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by th |
|
| October 22, 2024 |
Exhibit 99.1 Ocuphire Pharma Announces Acquisition of Opus Genetics Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patien |
|
| October 22, 2024 |
AMENDED AND RESTATED BYLAWS OPUS GENETICS, INC. (A DELAWARE CORPORATION) OCTOBER 23, 2024 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF OPUS GENETICS, INC. (A DELAWARE CORPORATION) OCTOBER 23, 2024 Table of Contents Page ARTICLE I. OFFICES 1 Section 1. Registered Office. 1 Section 2. Other Office. 1 ARTICLE II. CORPORATE SEAL 1 Section 3. Corporate Seal. 1 ARTICLE III. STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings. 1 Section 5. Annual Meetings. 1 Section 6. Special Meetings. 11 Se |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission F |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Ocuphire Pharma, Inc. |
|
| August 13, 2024 |
Exhibit 10.1 OCUPHIRE PHARMA, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective Date: June 11, 2024 Each member of the Board of Directors (the “Board”) of OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will receive the comp |
|
| August 13, 2024 |
RESTATED CERTIFICATE OF INCORPORATION OCUPHIRE PHARMA, INC. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF OCUPHIRE PHARMA, INC. The present name of the corporation is Ocuphire Pharma, Inc. (the “Corporation”). The Corporation was incorporated under the name “CRS Delaware, Inc.” by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on January 14, 2005. This Restated Certificate of Incorporatio |
|
| August 13, 2024 |
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update Exhibit 99.1 Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3 |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 13, 2024 |
THIRD AMENDED AND RESTATED BYLAWS OCUPHIRE PHARMA, INC. (A DELAWARE CORPORATION) JUNE 11, 2024 Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF OCUPHIRE PHARMA, INC. (A DELAWARE CORPORATION) JUNE 11, 2024 Table of Contents Page ARTICLE I. OFFICES 1 Section 1. Registered Office. 1 Section 2. Other Office. 1 ARTICLE II. CORPORATE SEAL 1 Section 3. Corporate Seal. 1 ARTICLE III. STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings. 1 Section 5. Annual Meetings. 1 Section 6. Special Meetings. |
|
| June 13, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OCUPHIRE PHARMA, INC. (Pursuant to Sections 141 and 242 of the General Corporation Law of the State of Delaware) Ocuphire Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Delaware G |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2024 |
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update Exhibit 99.1 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced finan |
|
| May 10, 2024 |
Exhibit 99.1 NPDR Subset Analysis of ZETA-1 Phase 2 Trial A moderate to severe NPDR-qualifying subgroup analysis to inform future clinical trials NPDR, non-proliferative diabetic retinopathy. Primary endpoint: % of subjects with a ≥ 2 step improvement in monocular ETDRS DRSS at Week 24 Study eye: DR graded moderately severe to severe NPDR or mild PDR (monocular DRSS 47, 53, or 61) Fellow eye: No e |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Ocuphire Pharma, Inc. |
|
| May 10, 2024 |
AMENDMENT NO. 3 TO CONSULTING AGREEMENT Exhibit 10.1 AMENDMENT NO. 3 TO CONSULTING AGREEMENT This AMENDMENT NO. 3 (“Amendment No. 3”) to the CONSULTING AGREEMENT dated April 1, 2022, as amended on September 19, 2022, (the “Agreement”) between Ocuphire Pharma, Inc., a Delaware corporation having its principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, Michigan 48335 (the “Company”), and Jay S. Pepose, M.D |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2023 or □ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-34079 Ocuphire Pharma, Inc. (Exac |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 19, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 17, 2024 |
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made as of April 11, 2024 (the “Effective Date”), between Ocuphire Pharma, Inc., a Delaware corporation, having a principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, Michigan 48335 (the “Company”), and Jay S. Pepose, M.D., having an address at 1125 Templeton Place, Chesterfield MO, 6 |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 27, 2024 |
O c u p h i r e I n v e s t o r P r e s e n t a t i o n M a r c h 2 0 2 4 Exhibit 99. |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 8, 2024 |
Exhibit 99.1 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update FARMINGTON HILLS, Mich., March 8, 2024 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today anno |
|
| March 8, 2024 |
Ocuphire Pharma, Inc. Compensation Recovery Policy Exhibit 97 Ocuphire Pharma, Inc. Compensation Recovery Policy Adopted and approved on September 12, 2023 and Effective as of September 12, 2023 1. PURPOSE. OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company ha |
|
| March 8, 2024 |
LIST OF SUBSIDIARIES Subsidiaries of Ocuphire Pharma, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of Ocuphire Pharma, Inc. Subsidiaries Jurisdiction of Incorporation None |
|
| March 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-34079 Ocuphire Pharma, Inc. (Exac |
|
| March 8, 2024 |
Exhibit 10.5.5 FIFTH LEASE AMENDMENT This Lease Amendment made this 29th day of November, 2023 by and between DUKE & DUKE, a Limited Partnership, of 37000 Grand River Avenue, Suite 360, Farmington Hills, MI 48335, as "Landlord" and Ocuphire Pharma, Inc. of 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335, as "Tenant”. WITNESSETH WHEREAS, on or about May 19th, 2019, Landlord and Tena |
|
| February 16, 2024 |
Ocuphire Pharma Strengthens Leadership Team with Key Appointments Exhibit 99.1 Ocuphire Pharma Strengthens Leadership Team with Key Appointments Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., February 14, 2024 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused |
|
| February 16, 2024 |
Up to $50,000,000 of Shares of Common Stock and 246,792 Shares of Common Stock TABLE OF CONTENTS PROSPECTUS Up to $50,000,000 of Shares of Common Stock and 246,792 Shares of Common Stock This purchase agreement prospectus relates to the issuance and sale of up to $50,000,000 of shares of our common stock (“Purchase Shares”) that we may sell to Lincoln Park Capital Fund, LLC (“Lincoln Park”), from time to time pursuant to a purchase agreement, dated August 10, 2023 (the “Purchase Agreement”), that we have entered into with Lincoln Park, and an additional 246,792 shares of our common stock (the “Commitment Shares”) issued to Lincoln Park as commitment shares under the Purchase Agreement. |
|
| February 16, 2024 |
Exhibit 10.1 Employment Agreement THIS EMPLOYMENT AGREEMENT (this “Agreement”) by and between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and Nirav Jhaveri (the “Executive”) is signed by the Company and the Executive on February 13, 2024, and made effective as of the Effective Date (defined below). Recitals Whereas, the board of directors of the Company (the “Board”) has determi |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2024 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and Nirav Jhaveri (the “Executive”) is entered into and made effective as of February 12, 2024 (the “Amendment Date”). Recitals Whereas, the Company and the Executive entered into an Employment Agreement, effecti |
|
| January 22, 2024 |
January 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Lauren Hamill Re: Ocuphire Pharma, Inc. Registration Statement on Form S-3 File No. 333-276462 Acceleration Request Requested Date: January 23, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securiti |
|
| January 19, 2024 |
United States securities and exchange commission logo January 19, 2024 George Magrath Chief Executive Officer Ocuphire Pharma, Inc. |
|
| January 11, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Ocuphire Pharma, Inc. |
|
| January 11, 2024 |
As filed with the Securities and Exchange Commission on January 11, 2024 As filed with the Securities and Exchange Commission on January 11, 2024 Registration No. |
|
| January 10, 2024 |
Exhibit 4.16 OCUPHIRE PHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OCUPHIRE PHARMA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existin |
|
| January 10, 2024 |
Exhibit 4.15 OCUPHIRE PHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF 1 OCUPHIRE PHARMA, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under |
|
| January 10, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) Ocuphire Pharma, Inc. |
|
| January 10, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 10, 2024 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 10, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3516358 (State or other jurisdiction of incorporation |
|
| January 10, 2024 |
Exhibit 4.17 OCUPHIRE PHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OCUPHIRE PHARMA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existin |
|
| January 10, 2024 |
Exhibit 4.13 OCUPHIRE PHARMA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2 |
|
| December 6, 2023 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) by and between OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”), and RONIL PATEL (the “Executive”) is signed by the Company and the Executive and is entered into on and made effective as of April 24, 2023 (as defined below) (the “Effective Date”). RECITALS WHEREAS, the Company and the E |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Ocuphire Pharma, Inc. |
|
| December 6, 2023 |
FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.2 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and Ronil Patel (the “Executive”) is entered into and made effective as of December 1, 2023 (the “Amendment Date”). Recitals Whereas, on April 24, 2023, the Company and t |
|
| November 27, 2023 |
ACKNOWLEDGEMENT AND ACCEPTANCE Exhibit 10.1 November 17, 2023 Dear Joe, We are pleased to offer you employment with OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”). The terms of your offer of employment with the Company are as follows: Your initial position with us will be as Chief Operating Officer. Beginning on November 27, 2023 (the “Effective Date”), your annual base salary will be $ 400,000 paid in equal inst |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Ocuphire Pharma, Inc. |
|
| November 27, 2023 |
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer Exhibit 99.1 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial Operations FARMINGTON HILLS, Mich., November 27, 2023 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic bi |
|
| November 21, 2023 |
As filed with the Securities and Exchange Commission on November 20, 2023 As filed with the Securities and Exchange Commission on November 20, 2023 Registration No. |
|
| November 21, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Ocuphire Pharma, Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Ocuphire Pharma, Inc. |
|
| November 13, 2023 |
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update Exhibit 99.1 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3 Presbyopia Trial Met Primary Endpoint; Viatris Expected to Continue Phase 3 Developmen |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Ocuphire Pharma, Inc. |
|
| November 2, 2023 |
Exhibit 99.2 Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score Company Plans to Submit a Special Protocol Assessment (SPA) APX3330 has the Potential to be the First Oral Option for 8M Non-Proliferative Diabetic Retinopat |
|
| November 2, 2023 |
Exhibit 99.1 Ocuphire Corporate Presentation November 2023 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the success and timing of planned regulatory filings and approvals, pre-commercial activities, commercialization strategy and timelines, b |
|
| November 2, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Ocuphire Pharma, Inc. |
|
| November 1, 2023 |
FIRST AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN Exhibit 10.3 FIRST AMENDMENT TO OCUPHIRE PHARMA, INC. 2021 INDUCEMENT PLAN The Ocuphire Pharma, Inc. 2021 Inducement Plan (the “Plan”) is hereby amended in the following respects, effective November 1, 2023, in accordance with Section 2(b)(vi) of the Plan. The first sentence of Section 3(a) of the Plan is deleted in its entirety and replaced with the following sentence: “Subject to Section 9(a) re |
|
| November 1, 2023 |
Exhibit 99.1 Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development FARMINGTON HILLS, Mich., November 1, 2023 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused |
|
| November 1, 2023 |
false000122862700012286272023-10-302023-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Ocuphire Pharma, Inc. |
|
| November 1, 2023 |
Ocuphire Pharma, Inc. RSU Award Grant Notice (2021 Inducement Plan) Exhibit 10.2 Ocuphire Pharma, Inc. RSU Award Grant Notice (2021 Inducement Plan) Ocuphire Pharma, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2021 Inducement Plan (the “Plan”) and the |
|
| November 1, 2023 |
Exhibit 10.1 Employment Agreement THIS EMPLOYMENT AGREEMENT (this “Agreement”) by and between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and George Magrath (the “Executive”) is entered into by the Company and the Executive and made effective as of November 1, 2023 (the “Effective Date”). Recitals Whereas, the Board of Directors of the Company (the “Board”) has determined that i |
|
| September 27, 2023 |
Exhibit 99.1 Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 FARMINGTON HILLS, Mich., and PI |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 Ocuphire Pharma, Inc. |
|
| August 14, 2023 |
Up to $50,000,000 of Shares of Common Stock and 246,792 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-252715 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2021) Up to $50,000,000 of Shares of Common Stock and 246,792 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $50,000,000 of shares of our common stock (“Purchase Shares”) that we may sell to Lincoln Park Capi |
|
| August 11, 2023 |
SEPARATION AND RELEASE AGREEMENT Exhibit 10.3 SEPARATION AND RELEASE AGREEMENT THIS SEPARATION AND RELEASE AGREEMENT (this “Agreement”) is made and entered as of June 8, 2023 by and between OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”) and MINA SOOCH (“Executive). RECITALS WHEREAS, Executive has been employed as the President and Chief Executive Officer of the Company pursuant to an Amended and Restated Employment |
|
| August 11, 2023 |
Exhibit 10.1 Execution Version PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of August 10, 2023, by and between OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inves |
|
| August 11, 2023 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 10, 2023, by and between OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defin |
|
| August 11, 2023 |
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update Exhibit 99.1 Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire Common Share Purch |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34079 Ocuphire Pharma, Inc. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Ocuphire Pharma, Inc. |
|
| August 1, 2023 |
Exhibit 99.1 Restore Vision & Clarity Ocuphire Corporate Presentation August 2023 2 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the success and timing of planned regulatory filings and approvals, pre-commercial activities, commercialization |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2023 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 12, 2023 |
United States securities and exchange commission logo July 12, 2023 Richard Rodgers Interim President and Chief Executive Officer Ocuphire Pharma, Inc. |
|
| July 7, 2023 |
Ocuphire Pharma, Inc. 37000 Grand River Avenue, Suite 120 Farmington Hills, MI 48335 Ocuphire Pharma, Inc. 37000 Grand River Avenue, Suite 120 Farmington Hills, MI 48335 July 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tara Harkins and Kevin Kuhar Re: Ocuphire Pharma, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 30, 2023 File No. 001-34079 Dear Ms. Ha |
|
| June 28, 2023 |
United States securities and exchange commission logo June 28, 2023 Richard Rodgers Interim President and Chief Executive Officer Ocuphire Pharma, Inc. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 8, 2023 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| June 2, 2023 |
Exhibit 3.1 THIRD AMENDMENT TO THE SECOND AMENDED AND RESTATED BYLAWS of OCUPHIRE PHARMA, INC. The Second Amended and Restated Bylaws (the “Bylaws”), of Ocuphire Pharma, Inc., a Delaware corporation, are hereby amended as follows, effective as of June 1, 2023. 1. Section 8 of ARTICLE III of the Bylaws is hereby amended and restated in its entirety to read as follows: “Quorum. At all meetings of st |
|
| May 15, 2023 |
Exhibit 99.2 Ocuphire Corporate Presentation May 2023 Disclosures and Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the success and timing of planned regulatory filings and approvals, pre-commercial activities, comme |
|
| May 15, 2023 |
Exhibit 10.1 April 20, 2023 Richard Rodgers Re: Ocuphire Pharma, Inc. Interim President and CEO Consulting Letter Agreement Dear Richard: You have agreed to serve as Interim President and Chief Executive Officer (“Interim CEO”) of Ocuphire Pharma, Inc. (the “Company”) during the Company’s search for a permanent President and Chief Executive Officer (“Successor CEO”). This letter agreement (the “Ag |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2023 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2023 |
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update Exhibit 99.1 Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis (RM) Set for September 28, 2023; Nyxol Development and Commercial |
